目的:评价基于日间病房模式下炎症性肠病患者输注生物制剂的应用效果。方法:选取2023年1月~6月100例炎症性肠病住院患者设为对照组,采用常规护理管理模式。2023年7月~12月105例门诊患者设为观察组,采用日间病房模式。比较两组患者的平...目的:评价基于日间病房模式下炎症性肠病患者输注生物制剂的应用效果。方法:选取2023年1月~6月100例炎症性肠病住院患者设为对照组,采用常规护理管理模式。2023年7月~12月105例门诊患者设为观察组,采用日间病房模式。比较两组患者的平均住院费用、平均治疗时间及满意度。结果:两组患者在年龄、性别、文化程度、疾病诊断差异无统计学意义(P > 0.05)。观察组患者治疗时间短于对照组,医疗费用低于对照组,满意度评分高于对照组,差异有统计学意义(P Objective: This paper aims to evaluate the application effect of biologics infusion in patients with inflammatory bowel disease based on the day ward model. Method: 100 hospitalized patients with inflammatory bowel disease from January to June 2023 were selected as the control group, and conventional nursing management mode was adopted. From July to December 2023, 105 outpatient patients were selected as the observation group and treated in a day ward mode. The average hospitalization costs, average treatment time, and satisfaction between two groups of patients were compared. Results: There was no statistically significant difference in age, gender, educational level, and disease diagnosis between the two groups of patients (P > 0.05). The treatment time of the observation group patients was shorter than that of the control group, the medical expenses were lower than those of the control group, and the satisfaction score was higher than that of the control group, with statistical significance (P < 0.05). Conclusion: Under the daytime ward mode, the establishment of a biologics infusion management model for outpatient inflammatory bowel disease patients can shorten the treatment time, reduce the economic burden on patients, improve work efficiency and quality, enhance patient satisfaction, and improve the economic and social benefits of the hospital.展开更多
文摘目的:评价基于日间病房模式下炎症性肠病患者输注生物制剂的应用效果。方法:选取2023年1月~6月100例炎症性肠病住院患者设为对照组,采用常规护理管理模式。2023年7月~12月105例门诊患者设为观察组,采用日间病房模式。比较两组患者的平均住院费用、平均治疗时间及满意度。结果:两组患者在年龄、性别、文化程度、疾病诊断差异无统计学意义(P > 0.05)。观察组患者治疗时间短于对照组,医疗费用低于对照组,满意度评分高于对照组,差异有统计学意义(P Objective: This paper aims to evaluate the application effect of biologics infusion in patients with inflammatory bowel disease based on the day ward model. Method: 100 hospitalized patients with inflammatory bowel disease from January to June 2023 were selected as the control group, and conventional nursing management mode was adopted. From July to December 2023, 105 outpatient patients were selected as the observation group and treated in a day ward mode. The average hospitalization costs, average treatment time, and satisfaction between two groups of patients were compared. Results: There was no statistically significant difference in age, gender, educational level, and disease diagnosis between the two groups of patients (P > 0.05). The treatment time of the observation group patients was shorter than that of the control group, the medical expenses were lower than those of the control group, and the satisfaction score was higher than that of the control group, with statistical significance (P < 0.05). Conclusion: Under the daytime ward mode, the establishment of a biologics infusion management model for outpatient inflammatory bowel disease patients can shorten the treatment time, reduce the economic burden on patients, improve work efficiency and quality, enhance patient satisfaction, and improve the economic and social benefits of the hospital.
